Recombinant monoclonal antibody mAb 1339 is a human monoclonal antibody that specifically binds to human IL-6 and can be potentially used in the treatment of inflammatory diseases and autoimmune diseases.
Figure 1 mAb 1339 inhibits MM cell proliferation in a time and dose-dependent manner.
(A) IL-6 dependent INA-6 cells were cultured in the presence of murine, chimeric and humanized MAbs to IL-6, to gp130 or to gp80, as well as with isotype control Abs at various concentrations. Cell proliferation was assessed by [3H]thymidine uptake at 72 hours. (B) IL-6 dependent INA6 and XG1 cells were cultured in the presence of fully humanized anti-IL-6 MAb 1339, as well as with isotype Ab control at various concentrations for variable time (24-72 h) at 37°C. Data represent mean +/- SD of 4 independent experiments performed in triplicate. mAb 1339 inhibits IL-6 dependent MM cell growth in a dose dependent manner.
Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.
Figure 2 mAb 1339 overcomes the effect of BMSC on both IL-6 dependent and independent MM cell growth.
(A) INA-6 and XG-1 cells were cultured with BMSC and in the presence of isotype Ab control as well as different doses of mAb 1339 for 24-72 hours. Cell proliferation was assessed by [3H]thymidine uptake assay and presented as % change from control. (B) MM1S, MM1R and U266 cells were cultured with BMSC or 5 ng/ml of rIL-6 with and without 1 μg/ml of mAb 1339, for 48 hours. DNA synthesis was assessed by [³H] thymidine uptake assay and presented as counts per minute (cpm). (C) Primary CD138+ MM cells were incubated in the absence or presence of BMSC with and without mAb 1339 for 24 hours. mAb 1339 is able to overcome the promoting effects of BMSC on MM cell growth.
Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.
Figure 3 1339 inhibits STAT3, ERK1,2 and Akt signaling pathways.
MM1S cells were incubated with (A) IL-6 (5 ng/ml, 10 and 30 minutes) or (B) with BMSC supernatant (30 minutes) in the absence or presence of 0.1 and 1 ug/ml of mAb 1339. Cells were harvested and whole cell lysates were subjected to immunoblotting using indicated Abs. 1339 inhibits both IL-6- and BMSC-induced activation of ERK 1, 2 and STAT3 pathway in MM cells, while a relatively lesser effect was observed with activation of AKT, as shown by densitometric quantitation of band intensity from WB (C).
Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.
Figure 4 mAb 1339 enhances growth inhibitory effect of anti-MM agents in the context of BMSC
INA-6 and MM1S cells were cultured with BMSC in the absence or presence of mAb 1339 (1 μg/ml) and dexamethasone (1 μM), velcade (5nM), perifosine (2.5 μM), revlimid (5 μM) with (1 μg/ml) or without mAb 1339 for 48 hours. DNA synthesis was assessed by [³H] thymidine uptake assay and presented as % of control cells without mAb 1339 or other agents. The combination of mAb 1339 and other anti-MM agents resulted in significant (p < 0.05) and synergistic antiproliferative effect.
Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.
Figure 5 Additive in vivo effect of MAb 1339 in combination with dexamethasone in a murine model of human MM (SCID-hu).
(A) mAb 1339 (100 μg per mouse) was injected intraperitoneal (i.p.) in SCID mice and its pharmacokinetics was evaluated by quantification of MAbs concentration in serum. After a single injection of mAb 1339, peak serum levels were observed after 24 hours and the MAbs remained in circulation for more than 15 days. (B) After injection of INA-6 MM cells directly into the human bone implant, SCID-hu mice were monitored for productiron of shuIL-6R in murine sera as a marker for MM cell growth. After the first detection of shuIL-6R, mice were injected with isotype control (100 μg per mouse, 1×/week) (n=6), mAb 1339 (100 μg per mouse, 1×/week) (n=4), dexamethasone (1mg/kg, 3×/week) (n=4), or mAb 1339 plus dexamethasone (n=4). Baseline values before treatment were not significantly different among groups.
Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.
Figure 6 Effect of 1339 on osteoclastogenesis in vitro and bone remodeling in vivo.
(A) In order to evaluate the effect of inhibition of IL-6 by 1339 on osteoclast differentiation, human pre-OCs were stimulated with OC differentiation media in presence and absence of IL-6 with or without 1 μg/ml of isotype control or mAb 1339 for 7 days. At the end of the treatment period, cells were fixed, stained for TRAP and counted. Data are expressed as mean +/- SD and are presented as percentage change from control. (B-C) To evaluate the effects of 1339 on the bone compartment, SCID-hu mice were injected with INA-6 cells into the implanted bone and were treated with isotype control or mAb 1339 after first detection of tumor. One month after treatment, bone chips were retrieved and analyzed by micro-CT and histological examination. (B) A qualitative assessment of images obtained from micro-CT suggests resistance to osteolytic bone destruction by mAb 1339. (C) H&E staining showed increased bone tissue and decreased MM cell number in the treated samples compared to controls.
Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-239 | Anti-Human IL6 Recombinant Antibody (Elsilimomab) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 |
TAB-0022CL-S(P) | Mouse Anti-IL6 Recombinant Antibody; scFv Fragment (TAB-0022CL-S(P)) | Elisa, In vivo, FuncS, Block | Mouse scFv |
TAB-0023CL-S(P) | Mouse Anti-IL6 Recombinant Antibody; scFv Fragment (TAB-0023CL-S(P)) | Elisa, In vivo, FuncS, Block | Mouse scFv |
TAB-0171CL-F(E) | Mouse Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-0171CL-F(E)) | ELISA, Block, In vivo | Mouse Fab |
TAB-669LC-S(P) | Anti-human IL6 scFv Fragment (SK2) | ELISA |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-097 | Anti-Human IL6 Recombinant Antibody (Sirukumab) | FC, IP, ELISA, Neut, FuncS, IF, WB | IgG1 - kappa |
TAB-680LC-F(E) | Human Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-680LC-F(E)) | ELISA | Human Fab |
TAB-681LC-F(E) | Human Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-681LC-F(E)) | ELISA | Human Fab |
TAB-682LC-F(E) | Human Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-682LC-F(E)) | ELISA | Human Fab |
TAB-683LC-F(E) | Anti-human IL6 Fab Fragment (IL6gk3-2) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0026CL | Human Anti-IL6 Recombinant Antibody (TAB-0026CL) | Elisa, In vivo, FuncS, Block | Chimeric (mouse/human) IgG |
TAB-0026CL-F(E) | Human Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-0026CL-F(E)) | Elisa, In vivo, FuncS, Block | Chimeric (mouse/human) Fab |
TAB-670LC | Anti-human IL6 Recombinant Antibody (NTS) (TAB-670LC) | ELISA, Inhib | Chimeric antibody (mouse/human) |
TAB-670LC-F(E) | Anti-human IL6 Fab Fragment (NTS) | ELISA | Chimeric antibody (mouse/human) |
VS3-WK1519 | Human Anti-IL6 Recombinant Antibody (clone CLLB8) | ELISA, FC | Chimeric (mouse/human) IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0172CL | Human Anti-IL6 Recombinant Antibody (TAB-0172CL) | ELISA, Block, In vivo | Human IgG |
TAB-0173CL | Human Anti-IL6 Recombinant Antibody (TAB-0173CL) | ELISA, Block, In vivo | Human IgG1 |
TAB-0172CL-F(E) | Human Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-0172CL-F(E)) | ELISA, Block, In vivo | Humanized Fab |
TAB-0173CL-F(E) | Human Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-0173CL-F(E)) | ELISA, Block, In vivo | Humanized Fab |
TAB-678LC | Anti-human IL6 Recombinant Antibody (BA399) (TAB-678LC) | ELISA, FC, Inhib | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-037LC | Recombinant Anti-Human IL6 Antibody (Fab glycosylation) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-197LC | Recombinant Anti-Human IL6 Antibody (Non-glycosylated) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0284MZ | Chicken Anti-Interleukin-6 Polyclonal IgY | WB, Indirect ELISA | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1472CQ | Mouse Anti-IL6 Recombinant Antibody (clone AS16) | IHC, IP, Neut | Mouse IgG1 |
NEUT-1473CQ | Rat Anti-Il6 Recombinant Antibody (clone 20F3) | Block, ELISA, IHC-P, IP, Neut, WB | Rat IgG1 |
NEUT-1475CQ | Rat Anti-Il6 Recombinant Antibody (clone 10F9) | Neut | Rat IgG2a |
NEUT-1476CQ | Rat Anti-Il6 Recombinant Antibody (clone CBL112) | Neut, WB | Rat IgG1 |
NEUT-1477CQ | Rat Anti-Il6 Recombinant Antibody (clone CBL879) | FC, IHC, IP, Neut | Rat IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1474CQ | Rat Anti-Il6 Recombinant Antibody (clone 32C11) | Block, ELISA, WB | Rat IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1814 | Rabbit Anti-IL6 Recombinant Antibody (clone DS1814AB) | WB | Rabbit IgG |
MOR-4277 | Rabbit Anti-IL6 Recombinant Antibody (clone SI360DS) | ELISA | Rabbit IgG |
MOR-4622 | Rabbit Anti-IL6 Recombinant Antibody (clone TH135DS) | WB, ELISA | Rabbit IgG |
MOR-4623 | Rabbit Anti-IL6 Recombinant Antibody (clone TH136DS) | WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MHC-LC3429 | PE-B8/Human IL6 (ILKQKIALD) MHC Tetramer | FCM | |
MHC-LC3430 | APC-B8/Human IL6 (ILKQKIALD) MHC Tetramer | FCM |
CAT | Product Name | Application | Type |
---|---|---|---|
NS-043CN | Human Anti-IL6 Recombinant Antibody (NS-043CN) | ELISA, WB | Human IgG1 |
NS-043CN-F(E) | Human Anti-IL6 Recombinant Antibody; Fab Fragment (NS-043CN-F(E)) | ELISA, WB | Human Fab |
NS-043CN-S(P) | Human Anti-IL6 Recombinant Antibody; scFv Fragment (NS-043CN-S(P)) | ELISA, WB | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-588-FY-S(P) | Human Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-588-FY-S(P)) | ELISA | Human scFv |
HPAB-591-FY-S(P) | Human Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-591-FY-S(P)) | ELISA | Human scFv |
HPAB-S0076-YC-S(P) | Rabbit Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-S0076-YC-S(P)) | ELISA, WB, Block, FuncS | Rabbit scFv |
HPAB-S0077-YC-S(P) | Human Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-S0077-YC-S(P)) | ELISA, Block | Human scFv |
HPAB-S0083-YC-S(P) | Rabbit Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-S0083-YC-S(P)) | ELISA, Block | Rabbit scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-239 | Afuco™ Anti-IL6 ADCC Recombinant Antibody (Elsilimomab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-097 | Afuco™ Anti-IL6 ADCC Recombinant Antibody (Sirukumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
AFC-TAB-H26 | Afuco™ Anti-IL6 ADCC Recombinant Antibody (Enlimomab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
AFC-TAB-253 | Afuco™ Anti-IL6 ADCC Recombinant Antibody (Olokizumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-1250-FY | Mouse Anti-IL6 Recombinant Antibody (HPAB-1250-FY) | ELISA | Mouse IgG |
HPAB-1251-FY | Mouse Anti-IL6 Recombinant Antibody (HPAB-1251-FY) | ELISA | Mouse IgG |
HPAB-1252-FY | Mouse Anti-IL6 Recombinant Antibody (HPAB-1252-FY) | ELISA | Mouse IgG |
HPAB-1253-FY | Mouse Anti-IL6 Recombinant Antibody (HPAB-1253-FY) | ELISA | Mouse IgG |
HPAB-1254-FY | Mouse Anti-IL6 Recombinant Antibody (HPAB-1254-FY) | ELISA | Mouse IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-1250-FY-S(P) | Mouse Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-1250-FY-S(P)) | ELISA | Mouse scFv |
HPAB-1251-FY-S(P) | Mouse Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-1251-FY-S(P)) | ELISA | Mouse scFv |
HPAB-1252-FY-S(P) | Mouse Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-1252-FY-S(P)) | ELISA | Mouse scFv |
HPAB-1253-FY-S(P) | Mouse Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-1253-FY-S(P)) | ELISA | Mouse scFv |
HPAB-1254-FY-S(P) | Mouse Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-1254-FY-S(P)) | ELISA | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-S0166-YC | Camelid Anti-IL6 Recombinant Single Domain Antibody (clone 6D5) | ELISA | Camelid VHH |
HPAB-S0167-YC | Camelid Anti-IL6 Recombinant Single Domain Antibody (clone 8F2) | ELISA | Camelid VHH |
HPAB-S0168-YC | Camelid Anti-IL6 Recombinant Single Domain Antibody (clone 6B12) | ELISA, Inhib | Camelid VHH |
HPAB-S0169-YC | Camelid Anti-IL6 Recombinant Single Domain Antibody (clone 7G4) | ELISA, Inhib | Camelid VHH |
HPAB-S0170-YC | Camelid Anti-IL6 Recombinant Single Domain Antibody (clone 7G5) | ELISA, Inhib | Camelid VHH |
There are currently no Customer reviews or questions for TAB-674LC. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.